Document:

License Agreement by and between Samsung Electronics Co., Ltd. and Staktek.

 Exhibit 10.2 
  
 CONFIDENTIAL TREATMENT REQUESTED 
  
 LICENSE AGREEMENT 
  
 This License Agreement (“Agreement”) is between Staktek Group, L.P., including its affiliates (“Staktek”), and Samsung Electronics Co.,
Ltd., including its affiliates (together with Staktek, the “Parties”). This Agreement is effective as of July 18, 2005 (“Effective Date”). 
  
 In consideration of the promises made herein and other good and valuable consideration, the receipt of and sufficiency of which are hereby
acknowledged, the Parties agree as follows: 
  

	1.	DEFINITIONS 

  
 Capitalized terms used in this Agreement and not otherwise defined have the meanings set forth below. 
  

	1.1	“Licensed Intellectual Property Rights” or “Licensed IPR” shall mean any and all Staktek Patents (as defined below).

  

	1.2	A “Licensed Product” is a stack made only of two or more vertically-stacked monolithic or multi-die memory devices, each individually encapsulated in
leaded plastic packages, the two or more leaded memory devices being connected by a flexible circuit connector there-between. Licensed Products do not include products that interpose between memory devices a printed circuit board, substrate, or flex
circuit large enough to carry more than one memory device on a side (for example, DIMMs and like products are not Licensed Products). 

  

	1.3	“Royalty” – see Section 4 of this Agreement. 

  

	1.4	A Licensed Product shall be considered “Sold” when such Licensed Product is shipped by Samsung, and whether alone or as part of a different product
such as, for example, a DIMM or video camera, excluding, however, any and all Licensed Products returned to Samsung. 

  

	1.5	“Staktek Patents” shall refer to any and all patents and patent applications owned by Staktek that are issued or filed prior to the expiration of the
Term. Nothing in this Agreement shall require Staktek to maintain or enforce any patent or file or prosecute any patent application. 

  

	1.6	“Term” The Term of this Agreement shall be five (5) years from the Effective Date. 

  

	2.	OWNERSHIP OF INTELLECTUAL PROPERTY 

  
 Subject only to the license set forth below, Staktek owns and shall own all right, title and interest in and to the Staktek Patents, and nothing in the relationship
between the parties should be construed as nor will it act to assign or transfer any ownership rights in the Staktek Patents to Samsung. 
  
 ### Confidential treatment has been requested for portions of this exhibit. Information for which confidential treatment has been requested has been omitted and is
noted with “***”. A complete version of this exhibit has been filed separately with the Securities and Exchange Commission. 
  

 1 

 CONFIDENTIAL TREATMENT REQUESTED 
  

	3.	LICENSE 

  

	3.1	Grant. Pursuant to this Agreement, Staktek hereby grants to Samsung a limited, non-exclusive, non-sublicenseable (except as provided in 3.2 below), non-transferable,
worldwide license to use the Licensed IPR to make, have made, use, import, offer to sell or sell Licensed Products for the Term of this Agreement. 

  

	3.2	Have-Made Limitations. Samsung may employ a third party (the “Contractor”) to make Licensed Products for Samsung under a limited sublicense under which the
Contractor may use the Licensed IPR for the sole purpose of making Licensed Products for Samsung. The Contractor shall not receive any other rights or licenses under the Licensed IPR and shall, in any event, be prohibited from using the Licensed IPR
to make Licensed Products for its own benefit or for any third party other than Samsung. 

  

	4.	ROYALTY 

  
 Samsung shall pay to Staktek a royalty in U.S. Dollars (the “Royalty”) for each Licensed Product Sold anywhere. 
  

	4.1	How Royalty Calculated: Samsung shall pay a Royalty to Staktek based on the total number of Licensed Products Sold during a calendar quarter as provided in Exhibit
A. 

  

	4.2	When Royalty Due. Royalty payments for Licensed Products shall be paid no later than sixty (60) days after the end of the quarter during which the Licensed
Products were Sold anywhere worldwide, by, for, or under the direction of Samsung to any customer including, but not limited to, distributors, affiliates, subsidiaries, other licensees or end users. 

  

	4.3	Royalty Report. For each quarter during the Term, Samsung shall report to Staktek on all sales of Licensed Products on a quarterly basis no earlier than ten
(10) days and no later than twenty (20) days following the end of the calendar quarter during which those Licensed Products were Sold. Samsung shall state how many of each different type of Licensed Product was Sold. No costs, pricing
formulas or margin information need be reported. 

  

	4.4	Payment. Payment of the Royalties required by this Section 4 shall be paid to Staktek in U.S. Dollars via wire transfer to: 

  
 Guaranty Federal Bank 
 301 Congress Ave., #1500 
 Austin, TX 78701

 USA 
 Tel: 512/320-1253

 Account #: *** 
 ABA#: ***

 Account Name: Staktek Group L.P. 
  
 ### Confidential treatment has been requested for portions of this exhibit. Information for which confidential treatment has been requested has been omitted and is
noted with “***”. A complete version of this exhibit has been filed separately with the Securities and Exchange Commission. 
  

 2 

 CONFIDENTIAL TREATMENT REQUESTED 
  

 or as Staktek may from time to time otherwise designate. 
  

	5.	TERM, TERMINATION, and EXPIRATION 

  

	5.1	Term. This Agreement commences as of the Effective Date and shall remain in force for a Term of five (5) years after which, if not extended by the Parties, this
Agreement shall expire. 

  

	5.2	Termination. Either Party will have the right to terminate this Agreement if the other Party breaches any material term or condition of this Agreement and fails to
cure such breach within sixty (60) days after written notice from the other Party. 

  

	5.3	Effects of Termination or Expiration. In the event of termination or expiration of this Agreement, the license granted under Section 3 shall immediately and
automatically terminate and end. If the Agreement is terminated according to Section 5.2, any Licensed Products that have been manufactured but not Sold as of the termination date can only be Sold by Samsung after receiving written permission
from Staktek. If the Agreement expires, any Licensed Products that have been manufactured but not Sold as of the date of such expiration may be Sold, so long as Samsung reports to Staktek the quantity of such manufactured but unsold Licensed
Products as of the expiration date, and Samsung pays the Royalty due after such sale in accordance with Section 4 of this Agreement. In the case of either termination or expiration, the Royalty shall continue to be due and payable for any
Licensed Products Sold. Notwithstanding the foregoing, nothing in this Section 5 is intended to or shall be construed as implying a license to make, have made, use, or import Licensed Products after either expiration or termination of this
Agreement. 

  
 Except as otherwise set forth
herein, upon any termination or expiration of this Agreement, the rights and obligations of the Parties under Sections 6 and 8 will survive. 
  

	6.	AUDIT RIGHTS 

  
 At Staktek’s cost, Staktek shall have the right, upon reasonable notice, not more than once per annum and not later than three (3) months after the term of this Agreement, to have audited Samsung’s
books and records by an independent auditor only for the purposes of verifying Royalty obligations to Staktek. Samsung agrees to provide only to the independent auditor commercially reasonable access and allow copies to be made for such purposes,
understanding that Samsung shall not be required to disclose its costs, pricing formulas, or margin information. In the event of underpayment, Samsung shall pay the difference within (30) days plus interest. If the underpayment is in excess of
ten percent (10%), Samsung shall reimburse Staktek for the cost of the audit. Samsung agrees to retain all relevant records for three (3) years. 
  

	7.	PRESS RELEASE 

  
 The Parties agree to issue a mutually satisfactory press release announcing the entry into this Agreement within two (2) business days following its execution, which form of release is attached as Exhibit
B, but agree to keep all other terms of this Agreement confidential. The Parties acknowledge that Staktek is subject to the public disclosure requirements of the Securities and Exchange Commission and Nasdaq. 
  

 3 

 CONFIDENTIAL TREATMENT REQUESTED 
  

	8.	NO WARRANTIES 

  
 EXCEPT AS OTHERWISE EXPRESSLY SET FORTH HEREIN, ALL LICENSES PROVIDED BY STAKTEK TO SAMSUNG WILL BE FURNISHED ON AN “AS IS” BASIS WITHOUT WARRANTY OF ANY KIND, INCLUDING, WITHOUT LIMITATION, (I) ANY
WARRANTY THAT USE OF THE STAKTEK PATENTS OR MAKING, USING, SELLING, OFFERING FOR SALE, HAVING MADE, OR IMPORTING THE LICENSED PRODUCTS WILL BE FREE FROM ANY THIRD PARTY CLAIMS OF INFRINGEMENT OR MISAPPROPRIATION AND (II) ANY IMPLIED WARRANTIES OR
TERMS OF MERCHANTABILITY OR FITNESS, OR USE FOR A PARTICULAR PURPOSE. 
  

	9.	MISCELLANEOUS and LEGAL 

  

	9.1	Governing Law; Legal Actions; Jurisdiction. This Agreement shall be governed by and construed under the laws of the State of California without regard to conflicts of
laws provisions thereof. Any suit or other claim brought with respect to this Agreement shall be brought in the U.S. Federal courts of the Northern District of California. The Parties hereby waive any objection to personal jurisdiction or venue in
any proceedings before such courts and consent to the exercise of personal jurisdiction over them by such courts. 

  

	9.2	No Exclusivity. Nothing in this Agreement is intended to create (or shall be construed as creating) an exclusive arrangement between the Parties.

  

	9.3	Severability. In the event that any provision of this Agreement is declared invalid or becomes unlawful in its operation, such provision shall be deemed to be omitted
and shall not affect that validity or enforceability of any of the other provisions of this Agreement. 

  

	9.4	Assignment. Neither Party shall have any right or ability to assign, transfer or sublicense any obligations or benefit under this Agreement without the written consent
of the other. The Parties acknowledge that either of them may become party to one or more transactions in the form of a merger (including reincorporation merger), consolidation, reorganization, stock sale or exchange, sale of all or substantially
all of such Party’s assets or some similar or related transaction, in any case with the result being that the affected Party is the surviving entity or, if the affected Party is not the surviving entity, the surviving entity continues to
conduct business conducted by the affected Party prior to consummation of the transaction. No such transaction involving either Party will be deemed to be an assignment of this Agreement requiring consent of the other, unless the transaction
materially and adversely affects a Party’s ability to continue to perform its obligations in accordance with this Agreement. Subject to the foregoing, this Agreement will bind and inure to the benefit of the parties, their respective successors
and permitted assigns. 

  

	9.5	 Integration; Modifications; Counterparts. This Agreement constitutes the entire understanding between the Parties relating to the subject matter
hereof. This Agreement supersedes any previous negotiations, writings, letters of intent and understandings between the Parties pertaining to the subject matter of this Agreement. This Agreement may only be modified by a writing specifically stating
that it is a modification or amendment to this Agreement that is signed by an authorized representative of each Party. This Agreement 

  

 4 

 CONFIDENTIAL TREATMENT REQUESTED 
  

	 	 
may be executed in several counterparts, all of which, taken together, will constitute one single agreement between the Parties.

  

	9.6	Neutral Construction. This Agreement is deemed to have been negotiated and prepared at the joint, direction of the Parties, at arms length, with the advice of counsel.

  

	10.	LICENSE SCOPE EXPANSION DISCUSSIONS. 

  
 The Parties may discuss certain new Staktek technologies and products including, but not limited to, “Marfa.” Unless otherwise mutually agreed, any and all such
discussions shall be on a non-confidential basis. The Parties may agree in writing to expand this Agreement to include such products within the scope of a new category to be called New Licensed Products and they may negotiate a New Licensed Products
license grant and a New Products Royalty calculation concerning such New Licensed Products. Unless modified in writing by both Parties, Marfa and other such new technologies and products are not included in this Agreement. 
  

 5 

 CONFIDENTIAL TREATMENT REQUESTED 
  

 IN WITNESS WHEREOF, the Parties hereto, intending to be legally bound hereby, have each caused to be affixed
hereto its hand and seal the day indicated. 
  

			
	Staktek Group, L.P.
	
	By Staktek GP LLC, its general partner
		
	By:	 	/s/ Wayne R. Lieberman
	 Title:
	 	President
	
	 Date: July 17, 2005

	
	Samsung Electronics Co., Ltd.
	 
		
	By:	 	/s/ Jay Shim
	 Title: 
	 	VP
	
	 Date: July 18, 2005

  

 6 

 CONFIDENTIAL TREATMENT REQUESTED 
  

  
 Exhibit A

  
 Royalty Rates 
  
 The first *** Licensed Products per quarter: $*** per
Licensed Product 
  
 The next *** Licensed
Products per quarter: $*** per Licensed Product 
  
 All units over *** per quarter: $*** per Licensed Product 
  
 ###
Confidential treatment has been requested for portions of this exhibit. Information for which confidential treatment has been requested has been omitted and is noted with “***”. A complete version of this exhibit has been filed separately
with the Securities and Exchange Commission. 
  

 7 

 CONFIDENTIAL TREATMENT REQUESTED 
  

  
 Exhibit B

  
 Press Release 
  
 Samsung and Staktek Sign Expanded IP License Agreement 
  
 SEOUL, KOREA AND AUSTIN, TEXAS – July     , 2005
– Samsung Electronics Co., Ltd., the world leader in advanced memory technology, and Staktek Holdings, Inc. (NASDAQ: STAK), a world-leading provider of Intellectual Property and services for 3D engineering solutions, today announced the renewal
and expansion of the license agreement that they entered into in July of 2000 for stacking packaged DRAMs using Staktek’s stacking technology. 
  
 Under the terms of the expanded agreement, Samsung will be able to use Staktek’s leaded package stacking technology for any Samsung leaded device, such as DRAMs,
SRAMs and Flash memory, until 2010. 
  
 “We are pleased to be able to expand
our offering of Staktek’s technology in our products, stated                     , the
             of Samsung Electronics Co., Ltd. Samsung will continue to lead the way in attaining the highest density modules afforded by smaller geometries and accompanying
manufacturing refinements.” 
  
 “We are proud that our advanced stacking
technology, built on an extensive patent portfolio, will enable Samsung not only to continue to provide its current products, but to expand its product offerings,” stated James W. Cady, Staktek’s Chief Executive Officer. 
  
 “This agreement further solidifies our ongoing relationship as a provider of
memory-based intellectual property to Samsung. Samsung’s products are recognized around the world for their high quality and market leadership. This agreement enhances Samsung’s ability to lead the market in next-generation, high-capacity
solutions across multiple memory formats,” stated Wayne R. Lieberman, Staktek’s President. 
  
 About Samsung Electronics 
  
 About
Staktek 
  
 Staktek is a world-leading provider of intellectual property
and services for the next generation of 3D high-speed and high-capacity thermal management systems. Staktek’s Performance, Value and High Performance Stakpak® memory solutions increase operational performance by doubling, tripling or quadrupling the amount of memory in the same
physical footprint as required by standard packaging technology. With an IP portfolio of more than 140 patents and patent applications pending, the company offers flexibility for customers, including outsourced manufacturing, technology
licensing and custom engineering. Headquartered in Austin, Texas, Staktek operates two world-class manufacturing locations in Austin and Reynosa, Mexico. 
  
 Samsung and Staktek are trademarks of Samsung Electronics Co., Ltd. and Staktek Group L.P., respectively. 
  

 8Amendment to Regulatory Settlement Agreement

 Exhibit 10.1 
  
 AMENDMENT TO 
  
 REGULATORY SETTLEMENT AGREEMENT 
  
 On November 18, 2004, four substantially identical regulatory settlement agreements (each an “RSA”) were entered into among Provident Life
and Accident Insurance Company and Provident Life and Casualty Insurance Company (“Provident”), The Paul Revere Life Insurance Company (“Revere), Unum Life Insurance Company of America (“Unum”) (the “Companies”)
and First Unum Life Insurance Company (“First Unum”), their domestic insurance regulator (the “Lead Regulator”), the domestic insurance regulators of the other Companies (the “Lead Regulators”), the United States
Department of Labor (“DOL”), and the chief insurance regulators of forty-five other states and the District of Columbia (the “Participating Regulators”). The definitions and terms used in the RSA are applicable to this Amendment,
which is deemed to be an amendment to each RSA. 
  
 WHEREAS, the
Companies and First Unum have given due consideration to the Lead Regulators’ requests that they provide notice to certain claimants eligible to participate in the RSA Claim Reassessment Process who are not currently entitled to notice of their
eligibility under the terms of the RSA, which does not presently provide for written notice to eligible claimants whose claims were denied or terminated during the period from January 1, 1997 through December 31, 1999, and have considered
certain other related matters; 
  
 WHEREAS, the Companies believe
that the categories of eligible claimants who are not currently entitled to notice and should be reconsidered and provided notice of their eligibility are those claimants whose disability policies were written by Provident and Revere, since Unum
Corporation, the parent of Unum and First Unum, did not merge with Provident Companies, Inc. until June 30, 1999, and claim handling practices were not generally made uniform throughout the merged company until after January 1, 2000.
January 1, 2000 is the beginning date for eligible claimants who are entitled to receive notice under the terms of the RSA; 
  
 WHEREAS, the Companies also propose to inform claimants in writing of the circumstances under which they are entitled, as a result of the terms of the
RSA, to an independent medical examination as part of the review of their claim; 
  
 WHEREAS, the Companies confirm the weight that it provides in handling disability claims to the opinion of an attending physician; and 
  
 NOW, THEREFORE, pursuant to the amending provision of each RSA, each of Provident, Revere, Unum and First Unum, their Lead
Regulator, the Lead Regulators and the DOL hereby agree as follows: 
  

	1.	Section B.2.b of the RSA is amended to provide for the mailing of a notice substantially in the form of that set forth in Exhibit 1, Attachment A-1 or Attachment A-2, as
appropriate, to claimants referred to in Section B.2.b.2 of the RSA whose claims were made under disability insurance policies written by Provident or Revere; provided, however, this notice provision shall not apply to such claimants residing in any
state that has not joined the RSA and that has a separate settlement agreement with the Companies addressing the notice issue for claimants in that state. The notice provided for in this paragraph shall be modified in content to reflect any
provisions of the RSA applicable to Requesting Claimants, including the fact that the claims of those requesting reassessment, shall be reviewed after substantial completion of the reassessment of Specified Claimants’ claims. Such notices shall
be mailed no later than March 1, 2006. The continued use of the term “Requesting Claimants” as applied to the claimants referred to in this paragraph shall not imply any diminution in the Companies’ obligation to provide the
notice to such claimants which is required hereunder. 

  

 1 

	2.	Section B.2.b.4 of the RSA is amended to read as follows: 

  
 “The Company commits to use its best efforts to complete the Claim Reassessment Process by December 31, 2006, (except for the reassessment of
Requesting Claimants’ claims which shall be completed by June 30, 2007), although, for good cause shown, the Lead Regulators and the DOL may agree to extend either of the foregoing dates.” 
  

	3.	In Exhibit 1 of the RSA in Section II. f. the second sentence shall be deleted and the following sentence is substituted therefor: 

  
 “Claimants who come within the definition of Requesting Claimants must
comply with the response period set forth in any notice received pursuant to this Agreement or, if no notice is provided, make a request to the Company no later than June 30, 2006.” 
  

	4.	Exhibit 6 of the RSA is amended to add Section D to read as follows: 

  
 “As part of advising a claimant how to submit a claim or early in the process of reviewing an open claim and, in any event, prior to any decision
being made to deny a recently submitted claim or to close an open claim, claimants shall be informed in writing that it is their right or the right of their attending physician (either directly or through the claimant’s representative) to
request an IME of their medical condition, unless the decision is made to pay or continue to pay the claim.” 
  

	5.	Section B.3.c.(i) shall be amended by adding the following factor to others relating to increased focus on policies relating to medical evidence: 

  
 “Giving significant weight to an attending physician’s
(“AP”) opinion, if the AP is properly licensed and the claimed medical condition falls within the AP’s customary area of practice, unless the AP’s opinion is not well supported by medically acceptable clinical or diagnostic
standards and is inconsistent with other substantial evidence in the record. In order for an AP’s opinion to be rejected, the claim file must include specific reasons why the opinion is not well supported by medically acceptable clinical or
diagnostic standards and is inconsistent with other substantial evidence in the record.” 
  

	6.	This Amendment to each RSA is effective as of October 3, 2005. 

  

									
	 Authorizing Signatures for Provident RSA
	 	 	 	 
			
	 Provident Life and Accident Insurance Company
	 	 	 	 Provident Life and Casualty Insurance Company

					
	By:	 	/S/  THOMAS R. WATJEN	 	 	 	By:	 	/S/  THOMAS R. WATJEN
	 	 	Thomas R. Watjen	 	 	 	 	 	Thomas R. Watjen
	 	 	President and Chief Executive Officer	 	 	 	 	 	President and Chief Executive Officer
			
	 October 3, 2005
	 	 	 	 October 3, 2005

				
	 Authorizing Signature for Revere RSA
	 	 	 	 	 	 
				
	 The Paul Revere Life Insurance Company
	 	 	 	 	 	 

  

 2 

									
					
	 By:
	 	/S/  THOMAS R. WATJEN	 	 	 	 	 	 
	 	 	Thomas R. Watjen	 	 	 	 	 	 
	 	 	President and Chief Executive Officer	 	 	 	 	 	 
				
	 October 3, 2005
	 	 	 	 	 	 
				
	 Authorizing Signature for Unum RSA
	 	 	 	 	 	 
				
	 Unum Life Insurance Company of America
	 	 	 	 	 	 
					
	 By:
	 	/S/  THOMAS R. WATJEN	 	 	 	 	 	 
	 	 	Thomas R. Watjen	 	 	 	 	 	 
	 	 	President and Chief Executive Officer	 	 	 	 	 	 
				
	 October 3, 2005
	 	 	 	 	 	 

  

			
	 Authorizing Signature for First Unum RSA

	
	 First Unum Life Insurance Company

		
	By:	 	/S/  THOMAS R. WATJEN
	 	 	Thomas R. Watjen
	 	 	President and Chief Executive Officer

  
 October 3, 2005 
  
 Authorizing Signatures for the Lead Regulator
for each of Provident, Revere, Unum and First Unum RSA’s, respectively 
  

									
	 Maine Bureau of Insurance
	 	 	 	 Massachusetts Division of Insurance

					
	By:	 	/S/  ALESSANDRO A. IUPPA	 	 	 	By:	 	/S/  JULIANNE M. BOWLER
	 	 	Alessandro A. Iuppa,	 	 	 	 	 	Julianne M. Bowler,
	 	 	Superintendent	 	 	 	 	 	Commissioner
			
	 October 3, 2005
	 	 	 	 October 3, 2005

			
	 Tennessee Department of Commerce and Insurance
	 	 	 	 New York Department of Insurance

					
	 By:
	 	/S/  PAULA A. FLOWERS	 	 	 	 By:
	 	/S/  HOWARD D. MILLS
	 	 	Paula A. Flowers	 	 	 	 	 	Howard D. Mills
	 	 	Commissioner	 	 	 	 	 	Superintendent

  

 3 

									
			
	 October 4, 2005
	 	 	 	 October 6, 2005

	
	Authorizing Signatures for Lead Regulators for each of the Provident, Revere, Unum and First Unum RSA’s, respectively and as applicable
			
	Maine Bureau of Insurance	 	 	 	 Massachusetts Division of Insurance

					
	 By:
	 	/S/  ALESSANDRO A. IUPPA	 	 	 	 By:
	 	/S/  JULIANNE M. BOWLER
	 	 	Alessandro A. Iuppa	 	 	 	 	 	Julianne M. Bowler
	 	 	Superintendent	 	 	 	 	 	Commissioner
			
	 October 3, 2005
	 	 	 	 October 3, 2005

  

			
	 Tennessee Department of Commerce and Insurance

		
	By:	 	/S/  PAULA A. FLOWERS
	 	 	Paula A. Flowers
	 	 	Commissioner
	
	 October 4, 2005

  
 Authorizing Signature for the United States Department of Labor 
  
 Elaine L. Chao 
 Secretary of Labor 
  
 Ann L. Combs 
 Assistant Secretary 
 Employee Benefits Security Administration 
  

			
		
	By:	 	/S/  JAMES M. BENAGES
	 	 	James M. Benages
	 	 	Regional Director
	 	 	Employee Benefits Security Administration
	
	 October 3, 2005

  
 Post Office Address: 
  
 U. S. Department of Labor 
 Employee Benefits Security Administration 
 JFK Federal Building, Room 575 
 Boston, MA 02203 
 TEL: 617-565-9600 
 FAX: 617-565-9666 
  

 4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00092-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00092-of-00352.parquet"}]]